Caprogen DS 500 mg/2 ml (IM Injection)
2 ml ampoule: ৳ 650.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Hydroxyprogesterone caproate |
| Company | Nuvista pharma ltd |
| Also available as |
Indications
- Reduces the risk of preterm birth in women with a history of singleton spontaneous preterm birth
- Prevention of preterm labor in patients aged 16 years or older with a history of spontaneous preterm birth
Description
Synthetic steroid hormone similar to medroxyprogesterone acetate and megestrol acetate. Ester derivative of 17a-hydroxyprogesterone formed from caproic acid.
Pharmacology
Binds to progesterone receptors in the uterus, ovaries, breasts, and central nervous system. Regulates gene transcription, leading to an anti-inflammatory effect and maintenance of pregnancy.
Dosage & Administration
- Administer intramuscularly at a dose of 500 mg or 250 mg once weekly
- Begin treatment between 16 weeks, 0 days and 20 weeks, 6 days of gestation
- Continue administration once weekly until week 37 of gestation or delivery
- Injection process and site preparation instructions
Contraindications
- Thrombosis or thromboembolic disorders
- Known or suspected breast cancer or other hormone-sensitive cancer
- Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
- Cholestatic jaundice of pregnancy
- Liver tumors, benign or malignant, or active liver disease
- Uncontrolled hypertension
Side Effects
- Injection site reactions (pain, swelling, pruritus, nodule)
- Hives
- Itching
- Nausea
- Diarrhea
- Symptoms of blood clots and allergic reactions
Pregnancy & Lactation
- Pregnancy: Category B. No adequate and well-controlled studies in women during first trimester of pregnancy.
- Lactation: Detectable amounts in breast milk. Discontinue drug at 37 weeks of gestation or upon delivery
Precautions & Warnings
- Discontinue if thrombosis or thromboembolism occurs
- Consider discontinuing if allergic reactions occur
- Monitor pre-diabetic and diabetic women
- Monitor for fluid retention in specific conditions
- Monitor women with a history of clinical depression
- Carefully monitor women who develop jaundice or hypertension
Use in Special Populations
- Pediatric Use: Not indicated for use in pediatric patients
- Geriatric Use: Not evaluated in women >65 years of age
- Hepatic Impairment: Contraindicated in patients with liver tumors or active liver disease
- Renal Impairment: Effect on pharmacokinetics not evaluated
Overdose Effects
No adverse events associated with overdosage reported
Therapeutic Class
Hormone preparations for other uses
Storage Conditions
Store at controlled room temperature between 15°C to 30°C, protect from light, keep out of reach of children